| |  Online-Ressource |
|---|
| Verfasst von: | Weyerer, Veronika [VerfasserIn]  |
|---|
| | Strissel, Pamela L. [VerfasserIn] |
|---|
| | Strick, Reiner [VerfasserIn] |
|---|
| | Sikic, Danijel [VerfasserIn] |
|---|
| | Geppert, Carol I. [VerfasserIn] |
|---|
| | Bertz, Simone [VerfasserIn] |
|---|
| | Lange, Fabienne [VerfasserIn] |
|---|
| | Taubert, Helge [VerfasserIn] |
|---|
| | Wach, Sven [VerfasserIn] |
|---|
| | Breyer, Johannes [VerfasserIn] |
|---|
| | Bolenz, Christian [VerfasserIn] |
|---|
| | Erben, Philipp [VerfasserIn] |
|---|
| | Schmitz-Draeger, Bernd J. [VerfasserIn] |
|---|
| | Wullich, Bernd [VerfasserIn] |
|---|
| | Hartmann, Arndt [VerfasserIn] |
|---|
| | Eckstein, Markus [VerfasserIn] |
|---|
| Titel: | Integration of spatial PD-L1 expression with the tumor immune microenvironment outperforms standard PD-L1 scoring in outcome prediction of urothelial cancer patients |
|---|
| Verf.angabe: | Veronika Weyerer, Pamela L. Strissel, Reiner Strick, Danijel Sikic, Carol I. Geppert, Simone Bertz, Fabienne Lange, Helge Taubert, Sven Wach, Johannes Breyer, Christian Bolenz, Philipp Erben, Bernd J. Schmitz-Draeger, Bernd Wullich, Arndt Hartmann and Markus Eckstein |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 12 May 2021 |
|---|
| Umfang: | 15 S. |
|---|
| Fussnoten: | Gesehen am 16.09.2021 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 13(2021), 10, Artikel-ID 2327, Seite 1-15 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Background: Immune therapy has gained significant importance in managing urothelial cancer. The value of PD-L1 remains a matter of controversy, thus requiring an in-depth analysis of its biological and clinical relevance. Methods: A total of 193 tumors of muscle-invasive bladder cancer patients (MIBC) were assessed with four PD-L1 assays. PD-L1 scoring results were correlated with data from a comprehensive digital-spatial immune-profiling panel using descriptive statistics, hierarchical clustering and uni-/multivariable survival analyses. Results: PD-L1 scoring algorithms are heterogeneous (agreements from 63.1% to 87.7%), and stems from different constellations of immune and tumor cells (IC/TC). While Ventana IC5% algorithm identifies tumors with high inflammation and favorable baseline prognosis, CPS10 and the TCarea25%/ICarea25% algorithm identify tumors with TC and IC expression. Spatially organized immune phenotypes, which correlate either with high PD-L1 IC expression and favorable prognosis or constitutive PD-L1 TC expression and poor baseline prognosis, cannot be resolved properly by PD-L1 algorithms. PD-L1 negative tumors with relevant immune infiltration can be detected by sTILs scoring on HE slides and digital CD8+ scoring. Conclusions: Contemporary PD-L1 scoring algorithms are not sufficient to resolve spatially distributed MIBC immune phenotypes and their clinical implications. A more comprehensive view of immune phenotypes along with the integration of spatial PD-L1 expression on IC and TC is necessary in order to stratify patients for ICI. |
|---|
| DOI: | doi:10.3390/cancers13102327 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers13102327 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/13/10/2327 |
|---|
| | DOI: https://doi.org/10.3390/cancers13102327 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | bladder cancer |
|---|
| | immune phenotypes |
|---|
| | PD-1 |
|---|
| | PD-L1 |
|---|
| | TILs |
|---|
| | urothelial cancer |
|---|
| K10plus-PPN: | 1770842683 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Integration of spatial PD-L1 expression with the tumor immune microenvironment outperforms standard PD-L1 scoring in outcome prediction of urothelial cancer patients / Weyerer, Veronika [VerfasserIn]; 12 May 2021 (Online-Ressource)
